



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,075	02/05/2004	Sathyamangalam V. Balasubramanian	11520.0341	6030
26712	7590	10/05/2004	EXAMINER	
HODGSON RUSS LLP			MONDESI, ROBERT B	
ONE M & T PLAZA			ART UNIT	
SUITE 2000			PAPER NUMBER	
BUFFALO, NY 14203-2391			1653	

DATE MAILED: 10/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/773,075

Applicant(s)

BALASUBRAMANIAN ET AL.

Examiner

Robert B Mondesi

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) 1-9 and 18-21 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☒ Claim(s) 10-17 is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: ____.

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, drawn to a method for reducing the antigenicity of a therapeutic agent, classified in class 514, subclass 12.
- II. Claims 10-17, drawn to a method for reducing the immunogenicity of a therapeutic agent, classified in class 514, subclass 12.
- III. Claims 18-21, drawn to lipid-protein complexes, classified in class 530, subclass 359.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different functions, and different effects. The method of invention of Group I is a method for reducing the antigenicity of a therapeutic agent, the method of invention of Group II is a method for reducing the immunogenicity of a therapeutic agent.

Inventions III and I-II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Art Unit: 1653

process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in materially different process such as the process of making antibodies.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and different search restriction for examination purposes as indicated is proper.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

Art Unit: 1653

"Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

During a telephone conversation with Ranjana Kadle on September 17, 2004 a provisional election was made with traverse to prosecute the invention of Group II, claims 10-17. Affirmation of this election must be made by applicant in replying to this Office action. Claims 1-9 and 18-21 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Priority

The current application filed on February 05, 2004 claims priority to 60/445,134 filed on February, 05, 2003.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the

Art Unit: 1653

applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 10 and 12-16 are rejected under 35 U.S.C. 102(e) as being anticipated by Rosenblum et al. US Patent Application Publication No: 2003/0176331.

Rosenblum et al. teach a method of reducing the immunogenicity of a therapeutic agent that comprises a protein (0126) and is complexed with a serine containing phospholipid such as phosphatidyl serine, phosphatidyl choline or phosphatidyl ethanolamine (page 36, section 0382). Rosenblum et al. teach further that in certain embodiments, their invention concerns a novel composition comprising one or more lipids associated/complexed with a therapeutic polypeptide (page 36, section 0378) in the form of micelles (page 37, section 0397), or liposome (page 38, section 0403-0415) wherein the formation of the complex is performed in the presence of phosphate buffered saline solution. Rosenblum et al. also teach that the active compounds may be formulated into a composition in a neutral or salt form and salts formed with free carboxyl groups can be derived from inorganic bases such as sodium and calcium (page 34, section 0361). In regards to **claims 15 and 16** the specific ratios and amounts cited by applicants, are anticipated improvements of the method Rosenblum et al. and it is inherent that a person skill in the art would have improved the method of Rosenblum et al. as a normal optimization of the disclosed process. Thus Rosenblum et al. teach all the elements of **claims 10 and 12-16** and these claims are anticipated under 35 USC 102(b).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 10 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rosenblum et al. US Patent Application Publication No: 2003/0176331 in view of Kirby et al.

Rosenblum et al. teach a method of reducing the immunogenicity of a therapeutic agent as mentioned above. Rosenblum et al. do not teach that the mentioned therapeutic agent comprises Factor VIII. Kirby et al. teach a therapeutic agent comprising Factor VIII, that is complexed with phosphatidyl serine (Pages 34-38, Materials and methods). Hemophiliacs require the daily replacement of Factor VIII to prevent bleeding and the resulting deforming hemophilic anthropathy. However,

Art Unit: 1653

supplies have been inadequate and the problems in therapeutic use occur due to difficulty of isolation and purification or immunogenicity. There is a need for a more potent Factor VIII molecule that is less apt to cause production of inhibitory anti-bodies and evades the immune detection in patients who have already acquired anti-bodies to human Factor VIII. It would have been obvious to one of ordinary skill in the art at the time the invention was made to develop a method for the reduction of the immunogenicity of a complexed Factor VIII therapeutic composition for the advantages of a Factor VIII therapeutic composition that is less apt to cause the production of inhibitory anti-bodies and a Factor VIII therapeutic composition that evades immune detection in patients that have already acquired anti-bodies to Factor VIII as taught by Rosenblum et al. and Kirby et al., see Rosenblum et al. at page 2, section 0011.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1653

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).




Robert B Mondesi

Patent Examiner

Group 1653

09-24-04



ROBERT A. WAX
PRIMARY EXAMINER